SBC Medical Group Holdings Inc. Financial Update and Strategic Moves
SBC Medical Group Holdings Incorporated, a global operator and provider of management services and products for cosmetic treatment centers, has recently disclosed its financial results for the first quarter of 2025. The company, listed on the Nasdaq under the ticker symbol SBC, reported a total revenue of $47 million for the quarter ending March 31, 2025. This figure represents a 14% decrease compared to the same period in the previous year. Despite the decline in revenue, the company’s operating income stood at $24 million.
In a strategic move to enhance shareholder value, SBC Medical Group Holdings announced the approval of a share repurchase program. The program, approved by the Board of Directors, will commence on May 20, 2025, with a maximum aggregate amount of $5 million. The repurchase period is set to run from May 20, 2025, to May 20, 2026, and will be funded through surplus cash and future free cash flow. The company believes its current share price undervalues its business performance and market potential, prompting this decision.
To support the share repurchase initiative, SBC Medical Group Holdings has decided to defer a previously announced Bitcoin purchase plan worth JPY 1 billion. This decision underscores the company’s focus on capital allocation strategies that prioritize shareholder returns.
Company Overview
SBC Medical Group Holdings Inc. operates in the health care sector, specifically focusing on cosmetic treatment centers. The company is listed on the Nasdaq stock exchange and trades in USD. As of May 13, 2025, the close price of SBC Medical Group Holdings was $3.36. The company’s market capitalization stands at approximately $325.34 million. The 52-week high was recorded at $36.52 on May 30, 2024, while the 52-week low was $2.62 on March 5, 2025. The price-to-earnings ratio is currently 7.6.
Related News
In other industry news, Lucid Diagnostics, a subsidiary of PAVmed Inc., provided a business update and reported its first-quarter 2025 financial results. The company processed 3,034 EsoGuard® tests and recognized revenue of $0.8 million in the first quarter. Lucid Diagnostics secured capital to extend its runway well past key upcoming reimbursement milestones and ended the first quarter with over $40 million in pro forma cash.
Additionally, the SBC Awards recognized several companies in the gaming industry. ProgressPlay was shortlisted for the SBC Awards Europe 2025, while Kaizen Gaming was named Latin America’s Casino and Sportsbook Operator of the Year at the SBC Awards Americas 2025.